title: Illumina, Inc.
abstract: Illumina, Inc., based in San Diego (CA, USA), is a genomics tool company that develops and markets integrated array-based systems and assays for a broad range of applications including genotyping, gene expression and epigenetics. Product offerings range from focused assay sets (up to 1,536 multiplexed assays) to whole-genome analysis (>100,000 assays/sample). Illumina's two microarray platforms, the Sentrix Array Matrix and the Sentrix BeadChip, are characterized by small (3 microm) feature size, dense feature packing (over 10 million features can be deployed on a single microarray) and the ability to analyze, in parallel, multiple samples on the same device. Illumina has developed a spectrum of proprietary assays (GoldenGate, Infinium, and DASL) for application on our microarray platform. These assays have been successfully employed for a number of applications, including collection of the majority of the Phase I genotyping data for the International HapMap Project. Illumina are focusing our activities on extending the applications of the above assays and developing new assays for future products. Illumina's goal is to deliver high-performance, high-throughput solutions that enable researchers to expand experimental scale while reducing the cost of large-scale research.
authors.affiliation: Illumina Inc., 9885 Towne Centre Drive, San Diego, CA 92121, USA. Fsteemers@illumina.com
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Steemers
authors.forename: Kevin L
authors.initials: KL
authors.lastname: Gunderson
mesh_terms: D015870:Gene Expression; D020869:Gene Expression Profiling; D016678:Genome; D005838:Genotype; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis / Q000191:economics / Q000295:instrumentation* / Q000379:methods*